PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

被引:0
作者
Robert D. Morgan
Andrew R. Clamp
D. Gareth R. Evans
Richard J. Edmondson
Gordon C. Jayson
机构
[1] The Christie NHS Foundation Trust,Department of Medical Oncology
[2] The University of Manchester,Manchester Cancer Research Centre
[3] University of Manchester,Division of Evolution and Genomic Sciences, Manchester Academic Health Science Centre
[4] Central Manchester NHS Foundation Trust,Department of Obstetrics and Gynaecology, St Mary’s Hospital
[5] University of Manchester,Division of Cancer Sciences, Faculty of Biology, Medicine and Health
来源
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词
Ovarian cancer; Platinum sensitivity; PARP inhibitors; BRCA mutation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:647 / 658
页数:11
相关论文
共 308 条
[1]  
Jayson GC(2014)Front-line therapy of advanced ovarian cancer: new approaches Ovarian cancer Lancet 384 1376-1388
[2]  
Kohn EC(2017)New treatments in ovarian cancer Ann Oncol 28 viii46-viii50-529
[3]  
Kitchener HC(2017)Antiangiogenic therapy in oncology: current status and future directions Ann Oncol 28 viii57-viii60-917
[4]  
Ledermann JA(2016)PARP inhibitors in ovarian cancer Lancet 388 518-921
[5]  
Ledermann JA(2016)Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Ann Oncol 27 i40-i44-139
[6]  
Pujade-Lauraine E(2005)Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 913-380
[7]  
Jayson GC(2005)Regulation of homologous recombination in eukaryotes Nature 434 917-882
[8]  
Kerbel R(2010)Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls Annu Rev Genet 44 113-414
[9]  
Ellis LM(2017)Germline mutations in RAD51D confer susceptibility to ovarian cancer Gynecol Oncol 147 375-490
[10]  
Harris AL(2011)Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene Nat Genet 43 879-1107